Supernus Pharmaceuticals SUPN License — Revenue, remaining performance obligation, variable consideration amount

Similar metrics at other companies

MLTXLicense — Revenue remaining performance obligation additional variable consideration amount

$344.3M+6.2%

MLTXLicense — Variable consideration amount

$8.1M0.0%

PEGASubscription license — Revenue remaining performance obligation

$78.44M+73.6%

BCRXLicense and other revenues — Contract with customer, transaction price

$2.4M—

WBDContent Licensing Contracts — Remaining performance obligations

$4.53B—

WBDBrand Licensing Contracts — Remaining performance obligations

$3.95B—

Questions, answered.

What is Supernus Pharmaceuticals's license — revenue, remaining performance obligation, variable consideration amount?

Supernus Pharmaceuticals (SUPN) reported license — revenue, remaining performance obligation, variable consideration amount of $470M in Q1 2026.

What does license — revenue, remaining performance obligation, variable consideration amount mean?

This metric quantifies the portion of the transaction price allocated to remaining performance obligations that is considered variable, such as future milestone payments or royalties contingent on specific events. It highlights the potential future revenue upside tied to the successful commercialization or development progress of licensed assets. Investors use this to assess the long-term value and risk profile of existing licensing contracts.